Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital

Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Myung Jin, Moon, Sung Woo, Choi, Ji Soo, Lee, Sang Hoon, Lee, Su Hwan, Chung, Kyung Soo, Jung, Ji Ye, Kang, Young Ae, Park, Moo Suk, Kim, Young Sam, Chang, Joon, Kim, Song Yee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719184/
https://www.ncbi.nlm.nih.gov/pubmed/33277557
http://dx.doi.org/10.1038/s41598-020-77837-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719184/
https://www.ncbi.nlm.nih.gov/pubmed/33277557
http://dx.doi.org/10.1038/s41598-020-77837-x

Ejemplares similares